CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers. Under some conditions, TIM-3 expression has also been shown to be stimulatory. Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the circumstances under which TIM-3 can inhibit and activate T-cell responses. Here we show that TIM-3 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), another well-known molecule expressed on activated T cells and involved in T-cell inhibition. Biochemical, biophysical and X-ray crystallography studies show that the membrane-distal immunoglobulin-variable (IgV)-like amino-terminal domain of each is crucial to these interactions. The presence of CEACAM1 endows TIM-3 with inhibitory function. CEACAM1 facilitates the maturation and cell surface expression of TIM-3 by forming a heterodimeric interaction in cis through the highly related membrane-distal N-terminal domains of each molecule. CEACAM1 and TIM-3 also bind in trans through their N-terminal domains. Both cis and trans interactions between CEACAM1 and TIM-3 determine the tolerance-inducing function of TIM-3. In a mouse adoptive transfer colitis model, CEACAM1-deficient T cells are hyper-inflammatory with reduced cell surface expression of TIM-3 and regulatory cytokines, and this is restored by T-cell-specific CEACAM1 expression. During chronic viral infection and in a tumour environment, CEACAM1 and TIM-3 mark exhausted T cells. Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models. Thus, CEACAM1 serves as a heterophilic ligand for TIM-3 that is required for its ability to mediate T-cell inhibition, and this interaction has a crucial role in regulating autoimmunity and anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interaction between TIM-3 and its four ligands (galectin 9, high mobility group protein B1, phosphatidyl serine, and carcinoembryonic antigen cell adhesion molecule 1) can diminish anti-tumor immunity through a variety of mechanisms including inducing CD8+ T cell death and exhaustion (Huang et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Huang et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We stimulated primary microglia with galectin-9 and CEACAM1, both of which mediate TIM-3 function in T cells by phosphorylating Y256 and Y263 residues34,35. This treatment had no effect on pSMAD2 expression”
From Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease (2025) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · cited 2×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 4×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
InfluentialHaploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Multiple Sequence Alignment Using ClustalW and ClustalX
Thompson, J. D., Gibson, T. J., & Higgins, D. G. (2003) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi0203s00 · Cited by 2,971 · cited 1×
“In addition, multiple sequencealignmentswereperformedusingClustalW 45 .”
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. W. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910048675 · Cited by 2,860 · cited 2×
“ThedatawereprocessedwithMosflm 40 andthe CCP 4softwaresuite 41 .”
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419
Cited by
Items 401–500 of 718
The Role of TIM-3 in Glioblastoma Progression
Ahmady, F., Sharma, A., Achuthan, A. A., Kannourakis, G., & Luwor, R. B. (2025) · Cells · doi:10.3390/cells14050346 · Cited by 16
Pathogenesis Guided Therapeutic Management of COVID-19: An Immunological Perspective
Kumar, A., Prasoon, P., Shekhawat, P. S., Pareek, V., Faiq, M. A., Kumari, C., Narayan, R. K., Kulandhasamy, M., & Kant, K. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1840566 · Cited by 12
“More specifically, CEACAM1 is expressed on activated T cells and causes immunosuppression [76].”
BackgroundStudstill, C. J., & Hahm, B. (2021) · Viruses · doi:10.3390/v13101951 · Cited by 16
“Another ligand, Ceacam-1, was identified for Tim-3, which is vital for the inhibitory function of Tim-3 and is important for the role of Tim-3 in exhaustion in a tumor setting [74].”
BackgroundDysfunction of circulating CD3+CD56+ NKT-like cells in type 2 diabetes mellitus
Tang, L., Wang, H., Cao, K., Xu, C., Ma, A., Zheng, M., Xu, Y., & Zhang, M. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.83317 · Cited by 17
“It has been reported that Tim-3 negatively regulates T cell responses by promoting T cell exhaustion via interaction with Galectin -9 and CD66a [40, 41] .”
Ding, P., Du, Y., Jiang, X., Chen, H., & Li, H. (2024) · Pediatric Rheumatology · doi:10.1186/s12969-023-00949-x · Cited by 15
“The interaction between CEACAM1 and TIM-3 plays a crucial role in regulating autoimmunity and anti-tumor immunity [42, 43].”
BackgroundEmerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy
Verner, J. M., Arbuthnott, H. F., Ramachandran, R., Bharadwaj, M., Chaudhury, N., & Jou, E. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00219 · Cited by 15
Arabzadeh, A., McGregor, K., Breton, V., Kraak, L. V. D., Akavia, U. D., Greenwood, C. M. T., & Beauchemin, N. (2017) · Oncotarget · doi:10.18632/oncotarget.22236 · Cited by 13
“CEACAM1-L expression mediates tumor development within tumor cells directly (colon [12], melanoma [13], non-small-cell lung cancer [14], thyroid [15], gastric [16]) as well as indirectly via cells in the stromal compartment (endothelial cells [7, 17], CD11b+Gr1+ immature myeloid cells [18, 19], matrix metalloproteinas…”
BackgroundSelf-citationMonoclonal antibody against human Tim‐3 enhances antiviral immune response
Li, G., Hou, C., Dou, S., Zhang, J., Zhang, Y., Liu, Y., Wang, Z., He, X., Wang, R., Chen, G., et al. (2018) · Scandinavian Journal of Immunology · doi:10.1111/sji.12738 · Cited by 14
“These ligands are galectin‐9 (Gal‐9),(11,13) phosphatidylserine,(14) high mobility group box‐1 protein HMGB1(15) and carcinoembryonic antigen‐related cell adhesion molecule1 CEACAM1.(16)The engagement of Tim‐3 with its ligand galectin‐9, which is widely expressed in immune cells,(17,18) induces T cell tolerance.”
BackgroundCapitani, N., Patrussi, L., & Baldari, C. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011221 · Cited by 16
“Both soluble TIM-3 ligands, the lectin Galectin-9 and the adhesion molecule carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) trigger Y256 and Y263 phosphorylation [169].”
BackgroundThe tumor microenvironment: Thousand obstacles for effector T cells
Massa, C., & Seliger, B. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.004 · Cited by 16
Molecular mechanisms of immunoreceptors in platelets
Kuriri, F. A., O’Malley, C. J., & Jackson, D. E. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.01.019 · Cited by 13
Chaweephisal, P., Sosothikul, D., Polprasert, C., Wananukul, S., & Seksarn, P. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001954 · Cited by 13
Hsieh, H.-C., Ling, L.-L., & Yi-Ching, W. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01202-1 · Cited by 24
“In addition to Galectin-9, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) has been identified as a functional ligand for TIM-3, and it plays a role in mediating immune suppression and promoting T cell exhaustion through heterodimeric interaction and co-signaling [119, 120].”
CD8+ T cell-based immunotherapy: Promising frontier in human diseases
Ton, N. Q. C., Deka, G., & Park, P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116909 · Cited by 12
Dupuis, M. L., Fiori, V., Soriani, A., Ricci, B., Dominici, S., Moricoli, D., Ascione, A., Santoni, A., Magnani, M., & Cianfriglia, M. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000100 · Cited by 12
Friedrich, S.-K., Lang, P. A., Friebus‐Kardash, J., Duhan, V., Bezgovsek, J., & Lang, K. S. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13241 · Cited by 14
Kuzevanova, A. Y., Апанович, Н. В., Mansorunov, D., Коротаева, А. А., & Karpukhin, A. V. (2022) · Biomedicines · doi:10.3390/biomedicines10092081 · Cited by 13
“A synergistic antitumor effect has been shown with the simultaneous blockade of TIM-3 and CEACAM1, as well as CEACAM1 and PD-L1, on murine colorectal cancer tumors [36].”
BackgroundCombined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus
Nakamura, H., Konnai, S., Okagawa, T., Maekawa, N., Sajiki, Y., Watari, K., KAMITANI, K., Saito, M., Kato, Y., Suzuki, Y., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01430-22 · Cited by 13
“Interestingly, the inhibitory effects of TIM-3 are ineffective when Ceacam-1 is deficient (12, 17).”
Involvement of Tim-3 in Maternal-fetal Tolerance: A Review of Current Understanding
Meng, X., Luo, Y., Cui, L., & Wang, S. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.106115 · Cited by 11
“CEACAM-1 is a single-pass type I transmembrane protein with 12 isoforms identified as novel cell surface ligands for Tim-3[35].”
InfluentialImmune evasion and resistance in breast cancer
Ababneh, E., Velez, S., & Zhao, J. (2025) · American Journal of Cancer Research · doi:10.62347/pngt6996 · Cited by 16
Wei, J., Feng, L., & Wu, L. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.51 · Cited by 11
Qian, W., Huang, P., Liang, X., Chen, Y., & Guan, B. (2020) · Translational Cancer Research · doi:10.21037/tcr-19-2039 · Cited by 11
“CEACAM1 represents a novel multi-purpose therapeutic target for cancer immunotherapy (29,30).”
BackgroundStructure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer
Lu, X. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210806120904 · Cited by 11
How Tim proteins differentially exploit membrane features to attain robust target sensitivity
Kerr, D. H. S., Gong, Z., Suwatthee, T., Luoma, A., Roy, S., Scarpaci, R., Hwang, H. L., Henderson, J. M., Cao, K. D., Bu, W., et al. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.09.016 · Cited by 12
Wu, H., Zhu, J., Xu, X., Xing, H., Wang, M., Liang, L., Li, C., Jia, H., Shen, F., Huang, D., et al. (2021) · Small · doi:10.1002/smll.202105237 · Cited by 12
The study of immune checkpoint inhibitors in chronic hepatitis B virus infection
Li, S., Li, N., Yang, S., Deng, H., Li, Y., Wang, Y., Jiaqiang, Y., Lv, J., Dong, L., Yu, G., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108842 · Cited by 14
Appearance of tuft cells during prostate cancer progression
Vlajic, K., Kluger, H. P., Bie, W., Merrill, B. J., Nonn, L., Kajdacsy‐Balla, A., & Tyner, A. L. (2023) · Oncogene · doi:10.1038/s41388-023-02743-1 · Cited by 12
“An interesting ligand expressed in cancer tuft cells is CEACAM1 which can modulate and inhibit responses of several immune cell types such as Natural Killer (NK) or T cells [51, 52].”
BackgroundYadav, R., Hakobyan, N., & Wang, J. C. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512502 · Cited by 11
“There are four known ligands for TIM-3 namely galectin-9 (Gal-9) [84]—which has been reported to induce apoptosis in TH1 cells, High-mobility group protein B1 (HMGB1) [85]— known as “alarmin”, which is released from damaged cells and induces the activation of phagocytes, phosphatidylserine (PtdSer) [86]—“eat-me” signa…”
BackgroundHuang, Y., Yoon, C. H., Gandhi, A. K., Hanley, T., Castrillon, C. E., Kondo, Y., Lin, X., Kim, W., Yang, C., Driouchi, A., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00525-8 · Cited by 11
“The latter include human autoimmune diseases, such as celiac disease 21 and multiple sclerosis 72 , infections, such as human immunode fi ciency virus 8 , and tumors, such as colorectal cancer 73 , glioblastoma 74 , melanoma 75 and head and neck tumors 76 – 79 often in association with markers…”
BackgroundMethodResultInfluentialSelf-citationTemplate‐based modeling and ab‐initio docking using CoDock in CAPRI
Kong, R., Liu, R., Xu, X., Zhang, D., Xu, X., Shi, H., & Chang, S. (2020) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25892 · Cited by 13
“The cell adhesion protein CEACAM1 was modeled by using PDB 5DZL as the template.(51) The structure of 1104 KONG ET AL.”
MethodMansorunov, D., Апанович, Н. В., Апанович, П. В., Кипкеева, Ф. М., Музаффарова, Т. А., Kuzevanova, A. Y., Nikulin, M. P., Malikhova, O. A., & Karpukhin, A. V. (2021) · Diagnostics · doi:10.3390/diagnostics11122370 · Cited by 12
“CEACAM1 promotes the maturation and expression of Tim-3 on the cell surface through the formation of heterodimeric interactions [125].”
BackgroundTIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma
Valente, S., Nascimento, C., Gameiro, A., Ferreira, J. A., Correia, J., & Ferreira, F. (2023) · Cancers · doi:10.3390/cancers15020384 · Cited by 11
“When TIM-3 binds to either Gal-9 or Ceacam-1 [19,20], the conserved tyrosine residues (Y256 and Y263) in the cytoplasmic tail undergo phosphorylation, resulting in the detachment of Bat-3, thus allowing TIM-3 to play its inhibitory function by inactivation of Lck and, consequently, downregulation of the TCR proximal s…”
BackgroundWu, H., Wu, Z., Li, H., Wang, Z., Yao, C., Bao, J., Chen, B., Xu, S., Xia, E., Ye, D., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1392940 · Cited by 14
Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation
Ahmady, F., Curpen, P., Perriman, L., Teixeira, A. F., Wu, S., Zhu, H., Poddar, A., Jayachandran, A., Kannourakis, G., & Luwor, R. B. (2024) · Cells · doi:10.3390/cells13211777 · Cited by 10
Wiecken, M., Machiraju, D., Chakraborty, S., Mayr, E.-M., Lenoir, B., Eurich, R., Richter, J., Pfarr, N., Halama, N., & Hassel, J. C. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2430066 · Cited by 12
Li, Y., Li, T., Xiao, F., Wang, L., Liao, X., Zhang, W., & Kang, Y. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003606 · Cited by 10
“…that potentially mediate the interaction between macrophages and T cells were identified, namely, CD48, CD86, and CEACAM1, which are typically expressed on antigen-presenting cells and can bind to the inhibitory receptors 2B4, [26] CD152, [27] and TIM3, [28] on the surface of T cells, respectively.”
Yang, A., Zhou, M., Gao, Y., & Zhang, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114843 · Cited by 14
Sun, H., Huang, D., Zhang, H., Dong, M., Wang, S., Sun, M., Liu, J., Wang, Y., Qu, X., Li, X., et al. (2025) · MedComm – Oncology · doi:10.1002/mog2.70030 · Cited by 13
Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies
Alibrahim, M. N., Carbone, A., Alsaleh, N., & Gloghini, A. (2025) · Cancers · doi:10.3390/cancers17142292 · Cited by 14
“Its known ligands include galectin-9 (GAL-9) and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), both of which trigger downstream inhibitory signaling pathways that lead to T-cell exhaustion or apoptosis [91,92].”
Li, J., Liu, X., Duan, Y., Wang, H., Su, W., Wang, Y., Zhuang, G., & Fan, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.7786 · Cited by 10
“The co-blockade of CEACAM1 and Tim-3 resulted in a synergistic therapeutic effect in mouse colorectal cancer models (31).”
BackgroundPhosphoantigen-Stimulated γδ T Cells Suppress Natural Killer–Cell Responses to Missing-Self
Walwyn-Brown, K., Pugh, J. L., Cocker, A. T. H., Beyzaie, N., Singer, B. B., Olive, D., Guethlein, L. A., Parham, P., & Djaoud, Z. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0696 · Cited by 11
Immune Checkpoint Inhibitors Related to Cardiotoxicity
Chen, R., Zhou, M., & Zhu, F. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9110378 · Cited by 13
“Besides immunosuppressive treatment, conventional cardiac therapy should be initiated for patients with heart failure, ACS, and arrhythmias.”
BackgroundEmerging Targets of Immunotherapy in Gynecologic Cancer
Cheng, H., Zong, L., Kong, Y., Gu, Y. L., Yang, J., & Xiang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s282530 · Cited by 13
Cong, Y., Liu, J., Chen, G., & Qiao, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.723238 · Cited by 13
“Tim-3 inhibits cell proliferation, attenuates effective cytokine synthesis, and promotes apoptosis of activated T cells, by interacting with its ligands that bind to the Tim-3 extracellular immunoglobulin V domain (16).”
BackgroundLiu, J. M.-H., Chen, P. P., Uyeda, M. J., Cieniewicz, B., Sayitoğlu, E. C., Thomas, B. C., Sato, Y., Bacchetta, R., Cepika, A., & Roncarolo, M. G. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.05.010 · Cited by 13
Klaile, E., Müller, M. M., Zubiría-Barrera, C., Brehme, S., Klassert, T. E., Stock, M., Durotin, A., Nguyen, T. D., Feer, S., Singer, B. B., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02703 · Cited by 10
Mir, M. A., Sofi, S., & Qayoom, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00014-5 · Cited by 9
Ocaña‐Guzmán, R., Osorio-Pérez, D., & Chávez‐Galán, L. (2023) · Pharmaceuticals · doi:10.3390/ph16081119 · Cited by 11
Immune cell dysfunction: A critical player in development of diabetes complications
Saadh, M. J., Allela, O. Q. B., Kareem, R. A., Kyada, A., Malathi, H., Nathiya, D., Bhanot, D., Sameer, H. N., Hamad, A. K., Athab, Z. H., et al. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103510 · Cited by 21
Human γδ T Cell Function Is Impaired Upon Mevalonate Pathway Inhibition
Suen, T. K., Al, B., Ulas, T., Reusch, N., Bahrar, H., Bekkering, S., Bhat, J., Kabelitz, D., Schultze, J. L., van de Veerdonk, F. L., et al. (2025) · Immunology · doi:10.1111/imm.13931 · Cited by 10
“Therefore, we also assessed the expression of the checkpoint receptor ligands: PDL1, CD66a/c/e + , CD80, and CD86 on PBMCs in our cultures [58–60] (Figure 3E–”
Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy
Peng, Y., Zhan, L., Shi, J., Wang, J., Li, Y., Sun, X., Lv, J., Yang, H., Qiu, Z., Liu, X., et al. (2025) · MedComm · doi:10.1002/mco2.70321 · Cited by 15
Huang, P., Lv, C., Zhang, C., Feng, H., Li, C., Zhang, H., Ζhao, X., & Li, M. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1754788 · Cited by 10
“cells, and it is a marker of T cell depletion in chronic viral infection or tumor microenvironment [26].”
BackgroundIncreased CEACAM1 expression on peripheral blood neutrophils in patients with rheumatoid arthritis
Matsumoto, H., Fujita, Y., Onizawa, M., Saito, K., Sumichika, Y., Yoshida, S., Temmoku, J., Matsuoka, N., Yashiro‐Furuya, M., Asano, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978435 · Cited by 10
“Recently, it was demonstrated that CEACAM1 serves as a heterophilic ligand for TIM–3 in activated T cells and that this interaction is crucial for regulating autoimmunity (9).”
BackgroundKalinka‐Warzocha, E., Wojas‐Krawczyk, K., & Krawczyk, P. A. (2023) · Cancers · doi:10.3390/cancers15133499 · Cited by 10
Establishment of novel anti-TIM-3 antibodies interfering with its binding to ligands
Yan, Z., Ma, T., Wang, X., Yi, L., Wei, P., Zhang, H., & Wang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28126 · Cited by 10
“The binding site of Gal-9 is located opposite to that of CEACAM-1, HMGB-1, and PtdSer on TIM-3 [13,17,19,33,34].”
BackgroundMa, R.-X., Wei, J., & Hu, Y. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0461 · Cited by 12
Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis
Nagai, K. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.584382 · Cited by 10
Ogando‐Rivas, E., Castillo, P., Jones, N. T., Trivedi, V., Drake, J. A., Dechkovskaia, A. M., Candelario, K. M., Yang, C., & Mitchell, D. A. (2022) · Microbiology and Immunology · doi:10.1111/1348-0421.12967 · Cited by 10
“Tim3 has been considered an inhibitory receptor that induces tolerance and T‐cell exhaustion in cancers.(37) Lag3 has also been considered a negative regulatory receptor of T cells with MHC‐II (i.”
BackgroundZhang, Y., Wang, Y., Wu, W. H., Liu, P., Sun, S., Hong, M., Yuan, Y., Xia, Q., & Chen, Z. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24526 · Cited by 9
Williams, R. V., Rogals, M. J., Eletsky, A., Huang, C. C., Morris, L., Moremen, K. W., & Prestegard, J. H. (2022) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2022.107336 · Cited by 9
Vergote, I. B., Ray-Coquard, I. L., Lorusso, D., Oaknin, A., Cibula, D., & Gorp, T. V. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2179483 · Cited by 9
“which can inhibit anti-tumor immunity via interaction with its four ligands [36], and T cell immunoglobulin and ITIM domain (TIGIT), which also has a broad range of immunosuppressive targets [37,38].”
BackgroundTim-3: Biomarqueur et cible thérapeutique en cancérologie
Granier, C., Gey, A., Dariane, C., Méjean, A., Timsit, M., Blanc, C., Verkarre, V., Radulescu, C., Fabre, E., Vano, Y. A., et al. (2018) · médecine/sciences · doi:10.1051/medsci/20183403011 · Cited by 17
“Dans un modèle murin de cancer colorectal, le blocage simultané de Tim-3 et Ceacam-1 a une action anti-tumorale [16].”
BackgroundPrognostic implication of CEACAM1 expression in squamous cell carcinoma of the larynx: Pilot study
Lucarini, G., Zizzi, A., Re, M., Sayeed, M. A., Primio, R. D., & Rubini, C. (2018) · Head & Neck · doi:10.1002/hed.25589 · Cited by 9
“CEACAM1 expression mediates tumor development within tumor cells directly as in colon,(17) melanoma,(18) lung,(19) thyroid,(20) gastric tissue(21) as well as indirectly via cells of the stromal compartment, as endothelial cells,(22) matrix metalloproteinase 9-positive leukocytes,(23) tumor-associated macrophages,(24)…”
BackgroundLv, S., Luo, H., Huang, K., & Zhu, X. (2020) · Medical Science Monitor · doi:10.12659/msm.926440 · Cited by 10
“The TIM-3 marker, which plays a significant role in regulating T-cell exhaustion [29], was positively associated with the expression level of GPX1, indicating that GPX1 might be an essential factor in mediating TIM-3 and T-cell exhaustion.”
BackgroundUnderstanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy
Kolb, H. R., Borcherding, N. C., & Zhang, W. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6407-9_12 · Cited by 12
TIM3 is a context-dependent coregulator of cytotoxic T cell function
Alamir, H., Wong, C. C. W., Alsubaiti, A., Edmunds, G. L., Alismail, M., Huynh, L., Shi, Y., Lewis, P. A., Grant, T., Alsulaimani, S., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adk4594 · Cited by 10
HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
Nguyen, A., Brown, D., Krishnan, R., Bastin, D. J., Deng, L., Chen, L., Salem, O., Walsh, S. R., Bramson, J. L., & Wan, Y. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2181 · Cited by 10
Carcinoembryonic antigen‐related cell adhesion molecule 1 in cancer: Blessing or curse?
Götz, L., Rueckschloss, U., Najjar, S. M., Ergün, S., & Kleefeldt, F. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14337 · Cited by 8
Mechanism and function of CEACAM1 splice isoforms
Dery, K. J., Najjar, S. M., Beauchemin, N., Shively, J. E., & Kupiec‐Weglinski, J. W. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14350 · Cited by 8
Self-citationThe role of immunotherapy in targeting tumor microenvironment in genitourinary cancers
Kalemoglu, E., Jani, Y. C., Canaslan, K., & Bilen, M. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1506278 · Cited by 9
McLeod, R. L., Angagaw, M. H., Baral, T. N., Liu, L., Moniz, R. J., Laskey, J., Hsieh, S., Lee, M., Han, J., Issafras, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26108 · Cited by 8
“The anti-mouse CEACAM1 Ab, CC1, has been used in a number of preclinical studies to evaluate CEACAM1 as a potential anti-tumor target [17, 19, 21, 23], however we were not able to find any published studies describing the ligand blocking capacity of this antibody.”
BackgroundMethodInfluentialLuebke, A. M., Ricken, W., Kluth, M., Hube‐Magg, C., Schroeder, C., Büscheck, F., Möller, K., Dum, D., Höflmayer, D., Weidemann, S. A., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32957 · Cited by 8
“it acts as a coinhibitory receptor for the immune-inhibitor Tim3.(8) On endothelial cells, CEACAM1 is the coreceptor of vascular epithelial growth factor receptor 2.”
BackgroundHuman CEACAM1 N-domain dimerization is independent from glycan modifications
Dufrisne, M. B., Swope, N. K., Kieber, M. K., Yang, J., Han, J. I., Li, J. Z., Moremen, K. W., Prestegard, J. H., & Columbus, L. M. (2022) · Structure · doi:10.1016/j.str.2022.02.003 · Cited by 8
Zhang, W., Zhang, Q., Xie, Z., Che, L., Xia, T., Cai, X., & Liu, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.839957 · Cited by 9
Zhang, Y., Lu, L., & Zheng, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1140771 · Cited by 8
“Additionally, TIM-3 is a type I transmembrane protein that includes amucin stalk domain and a variable N-terminal Ig domain (Huang et al., 2015), and TIGIT is a receptor that modulates immunity and serves as an immunological checkpoint in both innate and adaptive immunity.”
BackgroundHigh affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals
Ryser, S., Estellés, A., Tenorio, E., Kauvar, L. M., & Gishizky, M. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181464 · Cited by 8
“Recently, it has been reported that TIM-3 can form heterodimers with CEACAM1 through their amino terminal Ig-V regions and that this interaction participates in immune tolerance induction [20, 21].”
Liu, Z., 刘风勋, Xie, J., Zhao, Z., Pan, S., Liu, D., Liu, Z., & Liu, Z. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0013 · Cited by 7
Shen, F., Li, L., Yang, D., Tang, Z., Zhang, L., Liu, K., Hou, W., Lu, Z., Fang, J.-Y., Qi, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2516574122 · Cited by 8
“6 B ) (36, 37).”
Immune checkpoint TIM-3 in tumor immunotherapy
Ma, S., Zhu, M., Ma, C., & Li, C. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025235 · Cited by 7
“Both murine and human TIM - 3 possess a common FG - CC ′ cleft in the IgV domain, which serves as the binding site for PtdSer, CEACAM1, and HMGB1 [13,20,38].”
InfluentialHong, J., Chen, X., Chen, L., Wang, Y., Huang, B., & Fang, H. (2023) · Cancer Management and Research · doi:10.2147/cmar.s407930 · Cited by 7
Prediction of the Peptide–TIM3 Binding Site in Inhibiting TIM3–Galectin 9 Binding Pathways
Odstrcil, R. E., Dutta, P., & Liu, J. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00487 · Cited by 7
Mahanti, K., & Bhattacharyya, S. (2023) · Translational research · doi:10.1016/j.trsl.2023.10.003 · Cited by 7
Liu, T., Cui, Y., Ouyang, Y., Wang, M., & Yue, S. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.03.022 · Cited by 7
Zhou, M., Jin, Z., Liu, Y., He, Y., Du, Y., Yang, C., Wang, Y., Hu, J., Cui, L., Gao, F., et al. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx060 · Cited by 9
“Huang YH and colleagues [38] found that by forming a heterodimeric interaction in ‘cis’ or ‘trans’, CEACAM1 serves as a heterophilic ligand for TIM-3.”
BackgroundVasudevaraja, V., Renbarger, J. L., Shah, R. G., Kinnebrew, G. H., Korc, M., Wang, L., Huo, Y., Liu, E., Li, L., & Cheng, L. (2017) · Quantitative Biology · doi:10.1007/s40484-017-0126-1 · Cited by 8
Wang, J., Uddin, M. N., Akter, R., & Wu, Y. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021360 · Cited by 9
Yang, L., Liu, Y., Zhang, B., Yu, M., Huang, F., Zeng, J., Lu, Y., & Yang, C. (2023) · Disease Markers · doi:10.1155/2023/3606362 · Cited by 7
“In recent years, it was found that the binding of CEACAM1 to TIM-3 mediates the function of suppressing T cells in autoimmunity and antitumor immunity [14, 15].”
BackgroundWeng, C., Hu, X., & Wang, Y. (2020) · 3 Biotech · doi:10.1007/s13205-020-2122-9 · Cited by 7
Song, P., Deng, H., Liu, Y., & Zhang, M. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01991-8 · Cited by 7
The emerging role of TIM-3 in colorectal cancer: a promising target for immunotherapy
Karami, R., Fathi, M., Jalali, P., Hassannia, H., Zarei, A., Hojjat‐Farsangi, M., & Jadidi‐Niaragh, F. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2442437 · Cited by 7
“According to the Tim-3 immune-regulatory function, proper binding of the IgV domain to its specific ligands is important to suppress anti-tumor responses [10,59,60].”
Phadke, M. S., Li, J., Sriramareddy, S. N., Rodríguez, P. C., Ruffell, B., Luca, V. C., Tran, T. T. T., Chen, Y. A., & Smalley, K. S. M. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012011 · Cited by 12
Rao, D., Wang, T., Fu, C., Luo, Y., Lu, J., Sun, Z., Yan, W., Liang, H., Xia, L., & Huang, W. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02465-9 · Cited by 9
“(4) Elevated expression of immune checkpoint molecules, such as PD-1, CTLA-4, T-cell immunoglobulin domain and mucin domain-3 (TIM3), and lymphocyte-activation gene 3 (LAG3) [6, 62, 63].”
Lin, D., Zhu, R.-C., Chun, T., Li, F., Gao, M., & Wang, Y. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1183326 · Cited by 6
“In a mouse adoptive transfer model of colitis, a lack of Ceacam1 (carcinoembryonic antigen cell adhesion molecule 1, a ligand of TIM-3) in T cells resulted in a hyperinflammatory profile with reduced expression of TIM-3 and a decrease in regulatory cytokines (20).”
BackgroundGao, L., Tian, Y., & Chen, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073954 · Cited by 6
“This interaction plays a crucial role in regulating both self-immunity and anti-tumor immunity [16].”
BackgroundSelenopolysaccharide Isolated from Lentinula edodes Mycelium Affects Human T-Cell Function
Kaleta, B., Zielniok, K., Roszczyk, A., Turło, J., & Zagożdżon, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111576 · Cited by 6
AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies
Musnier, A., Corde, Y., Verdier, A., Cortès, M., Pallandre, J., Dumet, C., Bouard, A., KESKES, A., Omahdi, Z., Puard, V., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1499810 · Cited by 7
Therapeutic potential of TIM-3 inhibition in cancer, viral infections, and autoimmune disorders
Manzoor, A., & Barakat, K. (2025) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2025.106826 · Cited by 6
Checkpoint Molecules in Rheumatology—or the Benefits of Being Exhausted
Greisen, S. R., & Deleuran, B. W. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-00991-2 · Cited by 7
Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas
He, G., Chen, Z., Zhuo, S., Tang, J., Hao, W., Yang, K., & Yang, C. (2022) · Human Cell · doi:10.1007/s13577-022-00791-5 · Cited by 6
“The correlation between the expression of immune checkpoint-related genes (CTLA4 [36], PDCD1 [37–39], CD274 [40, 41], HAVCR2 [38], CEACAM1 [42, 43], LAG3 [44, 45], and TIGIT [46]) and risk score in the CGGA (Fig.”
BackgroundDong, W., Li, W., Zhang, S., Zeng, X., Qin, Q. S., Fan, H., Tang, Z., Wu, X., & Lu, G. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5228 · Cited by 6
Metadata
- Authors
- Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., Clayton, K. L., Raab, M., Chen, Q., Beauchemin, N., Yazaki, P. J., Pyzik, M., Ostrowski, M. A., Glickman, J. N., Rudd, C. E., Ploegh, H. L., Franke, A., Petsko, G. A., Kuchroo, V. K., & Blumberg, R. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Brandeis University (US)
- Massachusetts Institute of Technology (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Oslo University Hospital (NO)
- University of Toronto (CA)
- University of Cambridge (GB)
- Sichuan University (CN)
- McGill University (CA)
- City Of Hope National Medical Center (US)
- St. Michael's Hospital (CA)
- Corresponding author
- Blumberg, Richard S.
- ORCID
- Venue
- Nature
- Published
- 2014-10-26
- Volume
- 517
- Issue
- 7534
- Pages
- 386-390
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4297519
- OpenAlex
- W2122730216
- Cited by
- 717
- References
- 58
- Citations by year
- 2026: 44 · 2025: 72 · 2024: 85 · 2023: 82 · 2022: 71 · 2021: 82 · 2020: 76 · 2019: 51 · 2018: 47 · 2017: 40 · 2016: 38 · 2015: 28
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001102)
- National Institute of General Medical Sciences (R01GM032415, T32GM007122, GM-32415, R37GM032415, P41GM111244, R01GM026788)
- National Institute of Allergy and Infectious Diseases (AI 056299, P01AI073748, AI039671, AI073748, P01AI056299, P01AI039671)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK044319, DK0034854, R01DK053056, DK088199, DK053056, R56DK053056, DK051362, R37DK044319, R01DK051362, P30DK034854, R01DK044319, R01DK088199)
- National Institute of Neurological Disorders and Stroke (NS045937, R01NS045937)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- TIM-3, T cell exhaustion, immune tolerance, immune checkpoint, T cell co-inhibition, T cell costimulation, colorectal cancer, antitumor immunity, T cell receptor signaling
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Cell Line, Disease Models, Animal, Female, Humans, Immune Tolerance, Inflammation, Ligands, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Models, Molecular, Mucous Membrane, Protein Conformation, Receptors, Virus, T-Lymphocytes, Colorectal Neoplasms, Autoimmunity, Antigens, CD, Cell Adhesion Molecules, Mice, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.